Patent protection for Wegovy — Novo Nordisk’s blockbuster weight loss drug, which contains the second generation GLP-1 active ingredient and is at least twice as effective — is expected to …
Sima Sistani, CEO, WW International, August 16, 2023. Scott Mlyn | CNBC WeightWatchers CEO Sima Sistani has sent an internal memo to employees attempting to reassure them that the financial …
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan Mcdermid | Reuters For all of the promise associated …
Sopa Images | Lightrocket | Getty Images Eli Lilly is shaking up the pharmaceutical industry with a new website offering telehealth prescriptions and direct home delivery of certain drugs, including …
Goldman Sachs recently added a number of stocks to its lists of top picks, and a number of them were given significant upside. Called the “Conviction List – Directors’ Cut,” …
For many struggling with obesity, new medications have been “a gift,” as Oprah Winfrey recently described it in declaring she was “done with the shaming.” Investors in drug manufacturers Novo …
The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said …
Game-changing anti-obesity medications have posed nothing short of an existential crisis for Weight Watchers parent WW International since they arrived on the scene, but CEO Sima Sistani has been confronting …
A selection of injector pens for the Saxenda weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. Jim Vondruska | Reuters Novo Nordisk‘s …
Goldman Sachs highlighted a slew of stocks on its U.S. “conviction list — director’s cut” selection, naming several “most differentiated buy recommendations,” in an August 1 research note. Goldman’s “directors’ …